Health

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led…

2 months ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

October 05, 2025 09:00 ET  | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…

2 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

October 03, 2025 16:05 ET  | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…

2 months ago

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness…

2 months ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025 16:01 ET  | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics,…

2 months ago

Contemporary Care Introduces TMS Therapy to Naples, Florida

Image by Contemporary Care NAPLES, Fla., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Contemporary Care today announced the availability of Transcranial…

2 months ago

Publication relating to transparency notifications

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025, 10:30 pm CET / 4:30 pm ET –…

2 months ago

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025 16:15 ET  | Source: Context Therapeutics Inc. PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc.…

2 months ago

Angelini Ventures Leads 12 Million Follow-On Investment in Serenis, a Fast-Growing Digital Mental and Physical Health Company

Through its investment, Angelini Ventures aims to promote the expansion and acceleration of Serenis’ digital health and wellbeing services and…

3 months ago

Appointment of Marc Le Bozec as Interim CEO

Appointment of Marc Le Bozec as Interim CEO Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173;…

3 months ago